Abstract 2329
Background
Stereotactic radiosurgery (SRS) is a noninvasive alternative to microsurgery in the management of acoustic neuromas. Single fraction Gamma Knife SRS of acoustic neuromas results in high rates of local control (85-97 %). CyberKnife (CK) Robotic SRS is an alternative technique delivering the same quality SRS but with the benefits of a frameless treatment system allowing for fractionated treatment. The body of evidence in its use for acoustic neuromas is less robust. We present mature outcomes of a large cohort of patients treated with CK at a single institution.
Methods
This study consisted of 120 acoustic neuroma patients treated with CK from Sept 2010 until March 2016. Patients with complete hearing loss were treated with a single 12 Gy fraction (6 Pts). Those with hearing preservation or moderate to large tumors were treated with 18 Gy in 3 fractions (114pts). Follow-up T2 axial MRIs (0.50 mm slice) were analyzed to evaluate rates of tumor control and incidence of pseudo-progression. To obtain volumetric response data, MRI images were contoured on PACs imaging station using Aquarius Net version 4.4.13 by a single radiation oncologist.
Results
Patients range in age from 15 to 91 (mean 58). The median follow up time was 60 months. Mean tumor size was 2.8 cm3 (Range 0.1-30). Progression occurred in 4 patients (local control rate of 97%). Pseudo-progression was seen in 17 cases. For patients with pseudo-progression mean time to the maximum imaged tumor volume post treatment was 5 months (Range of 3 to 12 months) with an average volume increase of 11% (Max 31%). Mean time to subsequent regression to pre-treatment size was 15 months (Range of 10-23) No pseudo-progression led to subsequent local recurrence. There were low rates of late toxicity. One patient who progressed suffered CN VII palsy prior to salvage surgery. All other patients had preserved CNV and CNVII function and there was no case of brain stem necrosis.
Conclusions
Cyberknife offered high rates of durable local control (97 %) for acoustic neuromas with low rates of toxicity. Pseudo-progression was seen in 14% of patients and was not a predictor for treatment failure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Malone: Honoraria (self): Janssen; Honoraria (self): Astellas; Travel / Accommodation / Expenses: TerSera; Honoraria (self): AstraZeneca; Honoraria (self): AMGEN; Travel / Accommodation / Expenses: Sanofi; Honoraria (self): Abbvie; Honoraria (self): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract